Jennifer Barrett, Associate Editor

Chronic liver disease and cirrhosis can contribute to the development of liver cancer, which affects approximately 33,000 individuals in the United States each year.

Officials with the FDA have approved elotuzumab (Empliciti) injection for intravenous use in combination with pomalidomide and dexamethasone for the treatment of certain patients with relapsed or refractory multiple myeloma.

If approved for this indication, dupilumab (Dupixent) will be the first systemic biologic medicine to treat adolescents with moderate-to-severe atopic dermatitis.

Targeting interleukin (IL)-17A and IL-22 proteins may help delay the development of hepatic fibrosis.

Study identifies potential risk factors for chemotherapy-induced febrile neutropenia in patients with cancer.

This approval marks the first and only oral film approved by the FDA to treat seizures associated with Lennox-Gastaut syndrome.

Tanezumab (Eli Lilly and Pfizer) reduced osteoarthritis pain by 50% or greater in more than half of patients in a study.

Phase 2b study results show durable responses rates and symptom improvement in patients with psoriatic arthritis.

Adalimumab-adaz (Hyrimoz), a biosimilar of Humira, is the third FDA-approved Sandoz biosimilar in the United States.

This approval marks the first anti-PD-1 regimen for the first-line treatment of squamous non-small cell lung cancer regardless of tumor expression status.

The expanded indication marks the first time an anti-PD-1 regimen has been approved in the first-line setting as both combination and monotherapy for squamous NSCLC, regardless of tumor PD-L1 expression status.

Hepatitis B virus infectivity can remain stable for up to 9 months and demonstrate high resilience to antiseptics.

Preliminary data show that treatment with anti-PD-1 inhibitors may be feasible in patients with HIV and cancer.

Avelumab, an immune checkpoint inhibitor, in combination with axitinib, a tyrosine kinase inhibitor, significantly improved progression-free survival in untreated renal cell carcinoma.

Under the proposed plan, Medicare payments for Part B drugs would be based on international prices.

Study evaluates when and how the increased risk of autoimmune thyroid disease develops in patients diagnosed with rheumatoid arthritis.

Sun Pharma announced the availability of its treatment for moderate-to-severe plaque psoriasis in the United States.

Biosimilars adalimumab and etanercept showed equivalent safety and efficacy to reference products in patients with rheumatoid arthritis.

New data show a survival benefit with pembrolizumab (Keytruda) as both a monotherapy and combination treatment with chemotherapy.

Tildrakizumab-asmn (Ilumya) is indicated for the treatment of moderate-to-severe plaque psoriasis in adults.

Tildrakizumab-asmn (Ilumya), an injectable interleukin-23 (IL-23) inhibitor, was approved by the FDA in March for adults who are candidates for systemic therapy or phototherapy.

Phase 3 data show combination therapy demonstrates clinical benefit as first-line treatment.

Amgen has announced that it will reduce the price of its cholesterol drug evolocumab (Repatha) by 60%, from its annual list price of $14,100.

Amgen will make evolocumab (Repatha) available at a list price of $5850, a 60% reduction from its annual list price of $14,1000.

Amgen will make evolocumab (Repatha) available at a list price of $5850, a 60% reduction from its annual list price of $14,100.

New analysis examines the role of the HIV/AIDS epidemic in cancer survival rates among adolescents and young adults.

Coinfection with HIV and tuberculosis may affect drug-related adverse events, hospital readmissions, and treatment duration.

Study explores the effect of microglia dysregulation on progression of neurodegeneration in disorders such as Alzheimer disease and amyotrophic lateral sclerosis.

ViiV Healthcare has submitted a New Drug Application (NDA) for its single-tablet, 2-drug regimen of dolutegravir (DTG) and lamivudine (3TC) for the treatment of HIV-1 infection.

Study compares 2-year survival between patients with metastatic non-small cell lung cancer treated at academic and community centers.